Table 1. Guideline Recommendations by Level (Quality) of Evidence.
| Guideline | No. | Year | Methodology | Level of Evidence, No. (%)a | ||
|---|---|---|---|---|---|---|
| A | B | C | ||||
| GIOP | 37 | 2010 | ACC/AHA | 13.0 (35) | 7.0 (19) | 17.0 (46) |
| JIA | 102 | 2011-2013b | Oxford | 1.7 (2) | 12.2 (12) | 88.1 (86) |
| Gout | 88 | 2012c | ACC/AHA | 18.5 (21) | 27.4 (31) | 42.1 (48) |
| LN | 33 | 2012 | ACC/AHA | 8.0 (24) | 2.0 (6) | 23.0 (70) |
| OA | 60 | 2012 | GRADE | 35.0 (58) | 10.0 (17) | 15.0 (25) |
| SpA | 38 | 2015 | GRADE | 11.0 (29) | 7.5 (20) | 19.5 (51) |
| PMR | 10 | 2015 | GRADE | 1.0 (10) | 4.5 (45) | 4.5 (45) |
| RA | 35 | 2015 | GRADE | 4.6 (13) | 6.1 (17) | 24.3 (69) |
| Total | 403 | 92.8 (23) | 76.7 (19) | 233.5 (58) | ||
| Median % (IQR) | 23.0 (12-30) | 18.0 (15-23) | 50.0 (46-70) | |||
Abbreviations: ACC/AHA, American College of Cardiology/American Heart Association; GIOP, glucocorticoid-induced osteoporosis; GRADE, Grading of Recommendations and Assessment, Development, and Evaluation scoring system; IQR, interquartile range; JIA, juvenile idiopathic arthritis; LN, lupus nephritis; OA, osteoarthritis; Oxford, Oxford Centre for Evidence-Based Medicine; PMR, polymyalgia rheumatica; RA, rheumatoid arthritis; SpA, spondyloarthritis.
a
Level A evidence to multiple randomized clinical trials (RCTs) or meta-analyses; level B to single RCT or nonrandomized studies; and level C to opinion of experts, case studies, or standard of care.
b
Includes JIA guidelines of 2011 and focused 2013 update.
c
Includes gout part 1 and part 2 guidelines.